The Competition Commission of South Africa has initiated another important complaint involving TB drugs

The Health Justice Initiative in South Africa has reported that the South African government is utilizing the Competition Act to investigate a complaint against Otsuka. The HJI has reported that the company is alleged to be engaging in exclusionary practices for the drug Delamanid. A hearing for the complaint has not been scheduled with the tribunal at this time.